Neoplasm Recurrence, Local

"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

Descriptor ID	D009364
MeSH Number(s)	C04.697.655 C23.550.727.655
Concept/Terms	Neoplasm Recurrence, Local Neoplasm Recurrence, Local Local Neoplasm Recurrences Locoregional Neoplasm Recurrence Recurrences, Local Neoplasm Neoplasm Recurrences, Local Recurrence, Local Neoplasm Recurrence, Locoregional Neoplasm Local Neoplasm Recurrence Neoplasm Recurrence, Locoregional Locoregional Neoplasm Recurrences Neoplasm Recurrences, Locoregional Recurrences, Locoregional Neoplasm

Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".

Diseases [C]
Neoplasms [C04]
Neoplastic Processes [C04.697]
Neoplasm Recurrence, Local [C04.697.655]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Neoplastic Processes [C23.550.727]
Neoplasm Recurrence, Local [C23.550.727.655]

Below are MeSH descriptors whose meaning is related to "Neoplasm Recurrence, Local".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.

Bar chart showing 932 publications over 30 distinct years, with a maximum of 49 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	8	11	19
1996	9	16	25
1997	5	17	22
1998	6	12	18
1999	6	12	18
2000	8	17	25
2001	12	16	28
2002	6	21	27
2003	13	18	31
2004	16	16	32
2005	24	25	49
2006	9	14	23
2007	12	14	26
2008	16	25	41
2009	19	22	41
2010	19	22	41
2011	28	20	48
2012	21	12	33
2013	19	7	26
2014	24	11	35
2015	17	12	29
2016	26	20	46
2017	17	22	39
2018	16	13	29
2019	12	11	23
2020	16	17	33
2021	15	25	40
2022	2	32	34
2023	5	20	25
2024	10	16	26

Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.

Brown JC, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, O'Reilly EM, Shields AF, Meyerhardt JA. Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). J Natl Cancer Inst. 2024 Dec 01; 116(12):2032-2039.

View in: PubMed
Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV, Benson J, Bese N, Boughey JC, Boyle MK, Diego EJ, Eden C, Eller R, Goldschmidt M, Hlavin C, Heidinger M, Jelinska J, Karadeniz Cakmak G, Kesmodel SB, King TA, Kuerer HM, Loesch J, Milardi F, Murawa D, Moo TA, Menes TS, Passeri D, Pastoriza JM, Perhavec A, Pislar N, Polidorio N, Rami A, Ryu JM, Schulz A, Sevilimedu V, Ugurlu MU, Uras C, van Hemert A, Wong SM, Yoo TR, Zhang JQ, Karanlik H, Cabioglu N, Peeters MV, Morrow M, Weber WP. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. J Clin Oncol. 2025 Mar; 43(7):810-820.

View in: PubMed
Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS, Kelly WK, Paller CJ, Markowski MC, Denmeade SR, King S, Sullivan R, Davicioni E, Proudfoot JA, Eisenberger MA, Carducci MA, Lotan TL, Antonarakis ES. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Oct 01; 10(10):1400-1408.

View in: PubMed
Fine RE, Gilmore RC, Tomkovich KR, Dietz JR, Berry MP, Hernandez LE, Columbus KS, Seedman SA, Fisher CS, Han LK, Manahan ER, Hicks RD, Vaidya RP, Curcio LD, Sevrukov AB, Kenler AS, Taback B, Chen M, Miller ME, Gold L, Anglin BV, Aoun HD, Simmons RM, Feldman SM, Boolbol SK. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Ann Surg Oncol. 2024 Oct; 31(11):7273-7283.

View in: PubMed
Yoo TR, Lee JY, Park H, Cho WK, Jeon S, Jun HR, Lee SB, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Jeong JH, Kim JE, Ahn JH, Jung KH, Kim SB, Lee HJ, Gong G, Kim J, Chun SM. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence. Sci Rep. 2024 08 31; 14(1):20252.

View in: PubMed
Farsi S, Gardner JR, King D, Sunde J, Moreno M, Vural E. Head and neck cancer surveillance: The value of computed tomography and clinical exam. Am J Otolaryngol. 2024 Nov-Dec; 45(6):104469.

View in: PubMed
Farsi S, Odom JQ, Gardner JR, Held M, King D, Sunde J, Vural E, Moreno MA. Oncological outcomes of partial thickness calvarial resection for locally advanced scalp malignancies. Am J Otolaryngol. 2024 Nov-Dec; 45(6):104456.

View in: PubMed
Shore N, Hafron J, Saltzstein D, Brown G, Belkoff L, Aggarwal P, Phillips J, Bhaumik A, McGowan T. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). J Urol. 2024 Nov; 212(5):682-691.

View in: PubMed
Sparano JA, Crager M, Gray RJ, Tang G, Hoag J, Baehner FL, Shak S, Makower DF, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Whelan TJ, Kaklamani VG, Wolmark N, Sledge GW, Stemmer SM. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. NEJM Evid. 2024 Aug; 3(8):EVIDoa2300267.

View in: PubMed
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 Jul 09; 8(13):3507-3518.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement